Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease
Open Access
- 1 March 2020
- journal article
- research article
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 14, 931-938
Abstract
Purpose: Dry eye disease (DED) is one of the most common ophthalmic disorders. Pathogenesis of the disease includes inflammation of the ocular surface and lacrimal gland. Two anti-inflammatory prescription treatments are currently available: cyclosporine ophthalmic emulsion 0.05% (CYC) and lifitegrast 5% ophthalmic solution (LIF). The objective of this survey-based study was to assess physician satisfaction with CYC and LIF for the treatment of DED. Methods: Physicians currently treating DED patients with CYC or LIF were asked to rate the experiences of their patients currently or formerly using CYC and LIF, and their own perspectives on the two treatments. Results: Twenty-one physicians participated in the survey, providing responses on behalf of 210 patients. Overall, physicians reported low levels of satisfaction with onset of action of CYC and LIF, and fewer than half considered either drug to be effective in managing symptoms or improving patient quality of life (QoL). Burning sensation and dysgeusia were the most frequently reported side effects. Onset of action and effectiveness after onset were the main switching drivers. Although two-thirds of physicians were satisfied with the overall effectiveness of CYC and LIF, all physicians agreed that more DED treatment options are needed, with > 50% strongly agreeing. Conclusion: Physicians perceived a gap in DED management with currently available topical anti-inflammatory agents. Although satisfaction with CYC and LIF was high, few physicians considered these medications to be effective in managing symptoms or improving QoL.Keywords
This publication has 15 references indexed in Scilit:
- Dry eye disease ranking among common reasons for seeking eye care in a large US claims databaseClinical Ophthalmology, 2019
- Dry Eye Syndrome Preferred Practice Pattern®Ophthalmology, 2019
- Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye diseaseEuropean Journal of Ophthalmology, 2018
- Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and OlderAmerican Journal of Ophthalmology, 2017
- TFOS DEWS II Management and Therapy ReportThe Ocular Surface, 2017
- Pan-European survey of the topical ocular use of cyclosporine AJournal Français d'Ophtalmologie, 2017
- Dry Eye Disease and Work Productivity Loss in Visual Display Users: The Osaka StudyAmerican Journal of Ophthalmology, 2014
- Dry Eye Medication Use and ExpendituresCornea, 2012
- Impact of Dry Eye Syndrome on Vision-Related Quality of LifeAmerican Journal of Ophthalmology, 2007
- Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease11Reprint requests to: Linda Lewis, 575 Anton Blvd, Suite 900, Costa Mesa, CA 92626.Ophthalmology, 2000